SMMT
Summit Therapeutics Inc.
Price Chart
Latest Quote
$13.75
-0.32 (-2.27%)
Current Price
| Previous Close | $14.07 |
| Open | $14.38 |
| Day High | $14.60 |
| Day Low | $13.56 |
| Volume | 7,255,913 |
Stock Information
| Shares Outstanding | 776.16M |
| Total Debt | $20.04M |
| Cash Equivalents | $598.73M |
| Net Income | $-1.21B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.67B |
| EPS (TTM) | $-1.59 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.19B |
| Income | $-1.21B |
| Book/sh | $0.70 |
| Cash/sh | $0.77 |
| Employees | 265 |
Financial Ratios
| Quick Ratio | 7.19 |
| Current Ratio | 7.41 |
| Debt/Eq | 3.67 |
Returns & Margins
| ROA | -148.16% |
| ROE | -270.95% |
Ownership
| Insider Ownership | 83.14% |
| Institutional Ownership | 15.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -11.63 |
| P/B | 19.53 |
Analyst Data
| Recommendation | buy |
| Target Price | $28.17 |
Technical Indicators
| SMA20 | $15.15 |
| SMA50 | $18.09 |
| SMA200 | $17.96 |
| RSI | 23.35 |
| ATR | 1.0557 |
| Shares Float | 134.52M |
| Short Float | 26.79% |
| Short Ratio | 7.77 |
| Volatility | -1.31 |
| Rel Volume | 1.23 |
Performance History
| Week | +5.12% |
| Month | -13.25% |
| Quarter | -12.53% |
| 6 Months | -20.20% |
| YTD | -21.52% |
| Year | -30.73% |
| 3 Years | +616.15% |
| 5 Years | +101.61% |
| 10 Years | +76.96% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $13.75 | 8,723,200 |
| 2026-06-17 | $14.07 | 5,961,600 |
| 2026-06-16 | $13.88 | 5,505,400 |
| 2026-06-15 | $14.13 | 8,529,400 |
| 2026-06-12 | $14.01 | 9,844,900 |
| 2026-06-11 | $13.08 | 9,289,800 |
| 2026-06-10 | $13.05 | 8,628,100 |
| 2026-06-09 | $14.29 | 5,034,900 |
| 2026-06-08 | $14.11 | 5,493,100 |
| 2026-06-05 | $14.77 | 6,516,700 |
| 2026-06-04 | $14.84 | 5,414,600 |
| 2026-06-03 | $15.07 | 4,371,800 |
| 2026-06-02 | $14.86 | 10,043,900 |
| 2026-06-01 | $15.71 | 19,587,400 |
| 2026-05-29 | $17.54 | 7,205,400 |
| 2026-05-28 | $17.41 | 4,361,300 |
| 2026-05-27 | $17.36 | 2,209,100 |
| 2026-05-26 | $17.00 | 5,257,400 |
| 2026-05-22 | $16.62 | 6,890,400 |
| 2026-05-21 | $17.47 | 3,373,900 |
| 2026-05-20 | $17.89 | 4,630,100 |
| 2026-05-19 | $15.85 | 2,644,200 |
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
đ° Latest News
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering
Insider Monkey âĸ 2026-06-13T15:28:46Z
Summit Therapeutics Halts US$500m Offering After Ivonescimab Trial Results
Simply Wall St. âĸ 2026-06-12T16:15:54Z
Stocks Settle Sharply Lower on Escalating Middle East Tensions
Barchart âĸ 2026-06-10T20:38:17Z
Stocks Resume Decline as Chipmakers and AI Companies Fall
Barchart âĸ 2026-06-10T15:21:45Z
Stocks Fall on Weakness in Tech and Trucking Companies
Barchart âĸ 2026-06-10T14:09:04Z
Why Is SMMT Stock Tumbling Today?
Stocktwits âĸ 2026-06-10T11:19:33Z
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
24/7 Wall St. âĸ 2026-06-07T13:30:55Z
Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock
Simply Wall St. âĸ 2026-06-07T12:59:21Z
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data
Insider Monkey âĸ 2026-06-05T16:36:16Z
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
Zacks âĸ 2026-06-04T16:00:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $705,000 |
| Operating Revenue | $0 | $0 | $0 | $705,000 |
| Expenses | ||||
| Interest Expense | $0 | $8,686,000 | $16,461,000 | $4,401,000 |
| Total Expenses | $1,094,374,000 | $210,977,000 | $88,735,000 | $64,326,000 |
| Other Income Expense | $14,838,000 | $-1,638,000 | $-509,732,000 | $-12,273,000 |
| Other Non Operating Income Expenses | $-53,000 | - | $-252,000 | $304,000 |
| Net Non Operating Interest Income Expense | $0 | $-8,686,000 | $-16,461,000 | $-2,888,000 |
| Interest Expense Non Operating | $0 | $8,686,000 | $16,461,000 | $4,401,000 |
| Operating Expense | $1,094,374,000 | $210,977,000 | $88,735,000 | $64,326,000 |
| General And Administrative Expense | $556,700,000 | $60,200,000 | $29,264,000 | $26,743,000 |
| Other Operating Expenses | - | - | $-55,000 | $-9,893,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,079,586,000 | $-221,315,000 | $-614,928,000 | $-78,782,000 |
| Net Interest Income | $0 | $-8,686,000 | $-16,461,000 | $-2,888,000 |
| Normalized Income | $-1,094,477,000 | $-219,677,000 | $-105,448,000 | $-66,205,000 |
| Net Income From Continuing And Discontinued Operation | $-1,079,586,000 | $-221,315,000 | $-614,928,000 | $-78,782,000 |
| Net Income Common Stockholders | $-1,079,586,000 | $-221,315,000 | $-614,928,000 | $-78,782,000 |
| Net Income | $-1,079,586,000 | $-221,315,000 | $-614,928,000 | $-78,782,000 |
| Net Income Including Noncontrolling Interests | $-1,079,536,000 | $-221,301,000 | $-614,928,000 | $-78,782,000 |
| Net Income Continuous Operations | $-1,079,536,000 | $-221,301,000 | $-614,928,000 | $-78,782,000 |
| Pretax Income | $-1,079,536,000 | $-221,301,000 | $-614,928,000 | $-78,782,000 |
| Special Income Charges | $0 | $-15,007,000 | $-520,915,000 | $-8,468,000 |
| Operating Income | $-1,094,374,000 | $-210,977,000 | $-88,735,000 | $-63,621,000 |
| Interest Income | - | $13,466,000 | $10,403,000 | $1,513,000 |
| Total Operating Income As Reported | - | $-225,998,000 | $-609,650,000 | $-72,089,000 |
| Interest Income Non Operating | - | $13,466,000 | $10,403,000 | $1,513,000 |
| Per Share | ||||
| Diluted EPS | $-1.44 | $-0.31 | $-0.99 | $-0.41 |
| Basic EPS | $-1.44 | $-0.31 | $-0.99 | $-0.41 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,094,281,000 | $-210,888,000 | $-88,789,000 | $-60,541,000 |
| Total Unusual Items | $14,891,000 | $-1,638,000 | $-509,480,000 | $-12,577,000 |
| Total Unusual Items Excluding Goodwill | $14,891,000 | $-1,638,000 | $-509,480,000 | $-12,577,000 |
| Reconciled Depreciation | $146,000 | $89,000 | $198,000 | $1,263,000 |
| EBITDA (Bullshit earnings) | $-1,079,390,000 | $-212,526,000 | $-598,269,000 | $-73,118,000 |
| EBIT | $-1,079,536,000 | $-212,615,000 | $-598,467,000 | $-74,381,000 |
| Diluted Average Shares | $747,700,000 | $718,541,896 | $619,646,180 | $193,336,063 |
| Basic Average Shares | $747,700,000 | $718,541,896 | $619,646,180 | $193,336,063 |
| Diluted NI Availto Com Stockholders | $-1,079,586,000 | $-221,315,000 | $-614,928,000 | $-78,782,000 |
| Gain On Sale Of Security | $14,891,000 | $13,369,000 | $11,435,000 | $-4,109,000 |
| Research And Development | $537,674,000 | $150,777,000 | $59,471,000 | $51,999,000 |
| Selling General And Administration | $556,700,000 | $60,200,000 | $29,264,000 | $26,743,000 |
| Other Gand A | $20,000,000 | $10,500,000 | $29,264,000 | $26,743,000 |
| Salaries And Wages | $536,700,000 | $49,700,000 | $19,800,000 | $19,100,000 |
| Other Special Charges | - | $15,007,000 | $520,915,000 | - |
| Impairment Of Capital Assets | - | $0 | $0 | $8,468,000 |
| Other Taxes | - | $-313,000 | $-946,000 | $-4,523,000 |
| Tax Provision | - | - | - | - |
Fetched: 2026-06-11
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $656,859,000 | $386,884,000 | $75,799,000 | $124,856,000 |
| Total Assets | $751,182,000 | $435,560,000 | $202,949,000 | $664,168,000 |
| Total Non Current Assets | $30,881,000 | $11,810,000 | $13,237,000 | $7,456,000 |
| Other Non Current Assets | $7,205,000 | $2,548,000 | $4,322,000 | $577,000 |
| Goodwill And Other Intangible Assets | $2,001,000 | $1,864,000 | $1,893,000 | $1,798,000 |
| Current Assets | $720,301,000 | $423,750,000 | $189,712,000 | $656,712,000 |
| Other Current Assets | $6,537,000 | $11,076,000 | $2,622,000 | $486,000 |
| Restricted Cash | $316,000 | $325,000 | $0 | $300,000,000 |
| Cash Cash Equivalents And Short Term Investments | $713,448,000 | $412,349,000 | $186,242,000 | $348,607,000 |
| Cash And Cash Equivalents | $225,266,000 | $104,862,000 | $71,425,000 | $348,607,000 |
| Cash Equivalents | $208,900,000 | $88,599,000 | $60,357,000 | $286,513,000 |
| Cash Financial | $16,366,000 | $16,263,000 | $11,068,000 | $62,094,000 |
| Non Current Accounts Receivable | - | $698,000 | $959,000 | - |
| Receivables | - | $557,000 | $848,000 | $6,115,000 |
| Taxes Receivable | - | $557,000 | $848,000 | $5,766,000 |
| Prepaid Assets | - | - | $2,441,000 | $1,504,000 |
| Accounts Receivable | - | - | $0 | $349,000 |
| Other Receivables | - | - | - | $1,504,000 |
| Other Intangible Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $20,890,000 | $7,218,000 | $106,099,000 | $518,763,000 |
| Long Term Debt And Capital Lease Obligation | $17,502,000 | $3,453,000 | $103,290,000 | $497,303,000 |
| Current Debt And Capital Lease Obligation | $3,388,000 | $3,765,000 | $2,809,000 | $21,460,000 |
| Net Debt | - | - | $28,575,000 | $165,703,000 |
| Long Term Debt | - | - | $100,000,000 | $494,540,000 |
| Current Debt | - | - | - | $19,770,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $92,322,000 | $46,812,000 | $125,257,000 | $537,514,000 |
| Total Non Current Liabilities Net Minority Interest | $19,334,000 | $5,083,000 | $104,852,000 | $498,732,000 |
| Other Non Current Liabilities | $1,832,000 | $1,630,000 | $1,562,000 | $1,429,000 |
| Current Liabilities | $72,988,000 | $41,729,000 | $20,405,000 | $38,782,000 |
| Other Current Liabilities | $2,283,000 | $1,797,000 | $717,000 | $662,000 |
| Payables And Accrued Expenses | $52,392,000 | $24,190,000 | $11,450,000 | $11,019,000 |
| Payables | $20,292,000 | $4,636,000 | $2,667,000 | $355,000 |
| Accounts Payable | $20,292,000 | $4,636,000 | $2,667,000 | $355,000 |
| Current Notes Payable | - | - | $0 | $19,770,000 |
| Current Deferred Liabilities | - | - | - | $0 |
| Non Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $658,860,000 | $388,748,000 | $77,692,000 | $126,654,000 |
| Total Equity Gross Minority Interest | $658,860,000 | $388,748,000 | $77,692,000 | $126,654,000 |
| Stockholders Equity | $658,860,000 | $388,748,000 | $77,692,000 | $126,654,000 |
| Gains Losses Not Affecting Retained Earnings | $-2,540,000 | $-2,285,000 | $-2,448,000 | $-1,893,000 |
| Other Equity Adjustments | $-2,540,000 | $-2,285,000 | $-2,448,000 | $-1,893,000 |
| Retained Earnings | $-2,294,159,000 | $-1,214,573,000 | $-993,258,000 | $-378,330,000 |
| Other | ||||
| Ordinary Shares Number | $775,371,200 | $737,626,004 | $701,660,053 | $211,091,425 |
| Share Issued | $775,371,200 | $737,626,004 | $701,660,053 | $211,091,425 |
| Tangible Book Value | $656,859,000 | $386,884,000 | $75,799,000 | $124,856,000 |
| Invested Capital | $658,860,000 | $388,748,000 | $177,692,000 | $640,964,000 |
| Working Capital | $647,313,000 | $382,021,000 | $169,307,000 | $617,930,000 |
| Capital Lease Obligations | $20,890,000 | $7,218,000 | $6,099,000 | $4,453,000 |
| Total Capitalization | $658,860,000 | $388,748,000 | $177,692,000 | $621,194,000 |
| Additional Paid In Capital | $2,947,805,000 | $1,598,230,000 | $1,066,381,000 | $504,767,000 |
| Capital Stock | $7,754,000 | $7,376,000 | $7,017,000 | $2,110,000 |
| Common Stock | $7,754,000 | $7,376,000 | $7,017,000 | $2,110,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $17,502,000 | $3,453,000 | $3,290,000 | $2,763,000 |
| Current Capital Lease Obligation | $3,388,000 | $3,765,000 | $2,809,000 | $1,690,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $14,925,000 | $11,977,000 | $5,429,000 | $5,641,000 |
| Current Accrued Expenses | $32,100,000 | $19,554,000 | $8,783,000 | $10,664,000 |
| Goodwill | $2,001,000 | $1,864,000 | $1,893,000 | $1,798,000 |
| Net PPE | $21,675,000 | $7,398,000 | $6,063,000 | $5,081,000 |
| Gross PPE | $21,675,000 | $7,398,000 | $7,105,000 | $6,378,000 |
| Other Properties | $21,675,000 | $7,398,000 | $5,881,000 | $4,680,000 |
| Other Short Term Investments | $488,182,000 | $307,487,000 | $114,817,000 | $0 |
| Accumulated Depreciation | - | $-1,118,000 | $-1,042,000 | $-1,297,000 |
| Leases | - | $323,000 | $328,000 | $809,000 |
| Machinery Furniture Equipment | - | $1,028,000 | $896,000 | $889,000 |
| Properties | - | $0 | $0 | $0 |
| Current Deferred Revenue | - | - | - | $0 |
| Non Current Deferred Revenue | - | - | - | - |
Fetched: 2026-06-11
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-323,587,000 | $-142,245,000 | $-76,888,000 | $-42,206,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-322,930,000 | $-142,106,000 | $-76,760,000 | $-41,582,000 |
| Cash Flow From Continuing Operating Activities | $-322,930,000 | $-142,106,000 | $-76,760,000 | $-41,582,000 |
| Operating Gains Losses | $-320,000 | $229,000 | $-1,340,000 | $2,616,000 |
| Investing Activities | ||||
| Capital Expenditure | $-657,000 | $-139,000 | $-128,000 | $-624,000 |
| Investing Cash Flow | $-174,310,000 | $-205,341,000 | $-587,774,000 | $-624,000 |
| Cash Flow From Continuing Investing Activities | $-174,310,000 | $-205,341,000 | $-587,774,000 | $-624,000 |
| Net Other Investing Changes | - | $-15,007,000 | $-475,015,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $604,565,000 | $477,893,000 | $109,686,000 | $100,000,000 |
| Financing Cash Flow | $617,533,000 | $381,227,000 | $86,513,000 | $620,244,000 |
| Cash Flow From Continuing Financing Activities | $617,533,000 | $381,227,000 | $86,513,000 | $620,244,000 |
| Net Common Stock Issuance | $604,565,000 | $477,893,000 | $109,686,000 | $100,000,000 |
| Common Stock Issuance | $604,565,000 | $477,893,000 | $109,686,000 | $100,000,000 |
| Net Other Financing Charges | - | - | $-619,000 | $-155,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-100,000,000 | $-24,686,000 | $-25,000,000 |
| Interest Paid Supplemental Data | $0 | $8,806,000 | $10,650,000 | $434,000 |
| Income Tax Paid Supplemental Data | $0 | $0 | $52,000 | $0 |
| End Cash Position | $225,582,000 | $105,187,000 | $71,425,000 | $648,607,000 |
| Beginning Cash Position | $105,187,000 | $71,425,000 | $648,607,000 | $71,791,000 |
| Effect Of Exchange Rate Changes | $102,000 | $-18,000 | $839,000 | $-1,222,000 |
| Changes In Cash | $120,293,000 | $33,780,000 | $-578,021,000 | $578,038,000 |
| Proceeds From Stock Option Exercised | $12,968,000 | $3,334,000 | $2,132,000 | $399,000 |
| Net Issuance Payments Of Debt | $0 | $-100,000,000 | $-24,686,000 | $520,000,000 |
| Net Long Term Debt Issuance | $0 | $-100,000,000 | $-24,686,000 | $520,000,000 |
| Long Term Debt Payments | $0 | $-100,000,000 | $-24,686,000 | $-25,000,000 |
| Net Investment Purchase And Sale | $-173,653,000 | $-190,195,000 | $-112,857,000 | $0 |
| Sale Of Investment | $311,340,000 | $489,837,000 | $208,165,000 | $0 |
| Purchase Of Investment | $-484,993,000 | $-680,032,000 | $-321,022,000 | $0 |
| Net PPE Purchase And Sale | $-657,000 | $-139,000 | $98,000 | $-624,000 |
| Sale Of PPE | $0 | $0 | $226,000 | $0 |
| Purchase Of PPE | $-657,000 | $-139,000 | $-128,000 | $-624,000 |
| Change In Working Capital | $31,416,000 | $15,479,000 | $-516,000 | $9,867,000 |
| Change In Other Working Capital | $203,000 | $-167,000 | $-359,000 | $-7,126,000 |
| Change In Other Current Liabilities | $80,000 | $95,000 | $0 | $0 |
| Change In Other Current Assets | $-4,875,000 | $2,470,000 | $-3,421,000 | $215,000 |
| Change In Payables And Accrued Expense | $31,142,000 | $20,451,000 | $-349,000 | $2,259,000 |
| Change In Accrued Expense | $15,839,000 | $18,436,000 | $-2,612,000 | $6,391,000 |
| Change In Payable | $15,303,000 | $2,015,000 | $2,263,000 | $-4,132,000 |
| Change In Account Payable | $15,303,000 | $2,015,000 | $2,263,000 | $-4,132,000 |
| Change In Prepaid Assets | $4,866,000 | $-7,370,000 | $3,613,000 | $5,107,000 |
| Stock Based Compensation | $732,420,000 | $50,981,000 | $14,108,000 | $11,948,000 |
| Asset Impairment Charge | $0 | $0 | $474,000 | $8,468,000 |
| Amortization Of Securities | $-7,006,000 | $-2,576,000 | $-1,924,000 | $0 |
| Depreciation Amortization Depletion | $146,000 | $89,000 | $198,000 | $1,263,000 |
| Depreciation And Amortization | $146,000 | $89,000 | $198,000 | $1,263,000 |
| Depreciation | $146,000 | $89,000 | $198,000 | $349,000 |
| Net Foreign Currency Exchange Gain Loss | $-320,000 | $229,000 | $-1,231,000 | $2,616,000 |
| Net Income From Continuing Operations | $-1,079,586,000 | $-221,315,000 | $-614,928,000 | $-78,782,000 |
| Issuance Of Debt | - | $0 | $0 | $545,000,000 |
| Long Term Debt Issuance | - | $0 | $0 | $545,000,000 |
| Change In Receivables | - | $535,000 | $4,527,000 | $9,412,000 |
| Changes In Account Receivables | - | $0 | $359,000 | $975,000 |
| Other Non Cash Items | - | $15,007,000 | $527,168,000 | $3,038,000 |
| Amortization Cash Flow | - | $0 | $0 | $914,000 |
| Amortization Of Intangibles | - | $0 | $0 | $914,000 |
| Gain Loss On Sale Of PPE | - | - | $-109,000 | $0 |
Fetched: 2026-06-11